top of page
Search

Microbiome Therapeutics Market Share, Growth Drivers & Forecast 2034

  • Writer: Pallavi Garudkar
    Pallavi Garudkar
  • 2 days ago
  • 3 min read
Microbiome Therapeutics Market
Microbiome Therapeutics Market

Microbiome therapeutics are innovative treatments that modulate the human microbiome (gut bacteria, fungi, and viruses) to prevent or treat diseases. These therapies include live biotherapeutics, fecal microbiota transplantation (FMT), probiotics, and engineered microbial consortia. According to Fortune Business Insights the global microbiome therapeutics market size was valued at USD 288.8 million in 2025. The market is projected to grow from USD 366.7 million in 2026 to USD 4,023.1 million by 2034, exhibiting a CAGR of 34.90% during the forecast period.

This rapid growth is driven by breakthroughs in microbiome research, increasing prevalence of chronic diseases, and rising adoption of precision medicine.

Market Insights

  • Increasing understanding of the human microbiome’s role in health and disease is driving demand.

  • Rising prevalence of gastrointestinal disorders, metabolic diseases, and infections is boosting adoption.

  • Growing number of clinical trials and regulatory approvals for microbiome-based therapies is accelerating commercialization.

  • Advancements in genomics, bioinformatics, and AI-driven drug discovery are improving therapeutic development.

  • Increasing investments and partnerships between biotech firms and pharmaceutical companies are fueling innovation.

Market Segmentation Analysis

By Product Type

  • Fecal Microbiota Transplantation (FMT)

  • Probiotics

  • Prebiotics

  • Synbiotics

  • Live Biotherapeutic Products

FMT and live biotherapeutics dominate due to clinical effectiveness in treating infections like C. difficile, while next-generation engineered microbiome therapies are rapidly emerging.

By Application

  • Clostridioides difficile Infection (CDI)

  • Inflammatory Bowel Disease (IBD)

  • Metabolic Disorders

  • Cancer (Oncology)

  • Others

CDI dominates currently, accounting for a major share, while oncology and metabolic disorders are the fastest-growing segments due to expanding research.

By Route of Administration

  • Oral

  • Rectal

  • Injectable

Oral therapies are the fastest-growing segment due to ease of administration and patient compliance.

By End User

  • Hospitals & Clinics

  • Research Institutes

  • Specialty Pharmacies

Hospitals dominate due to higher patient inflow and advanced treatment facilities.

Regional Insights

  • North America: North America dominates the market with over 40.4% share in 2025, driven by strong R&D, regulatory approvals, and presence of key biotech companies.

  • Europe: Europe is the second-largest market, supported by increasing clinical trials and aging population.

  • Asia Pacific: Asia Pacific is the fastest-growing region, driven by expanding healthcare infrastructure, rising awareness, and increasing investments in biotechnology.

  • Rest of the World: Latin America and the Middle East & Africa are witnessing moderate growth due to improving healthcare systems and research initiatives.

Competitive Analysis

The microbiome therapeutics market is highly innovative and emerging, with strong competition among biotech startups and pharmaceutical companies.

Key strategies include:

  • Development of live biotherapeutic products and engineered microbiome drugs

  • Strategic collaborations and R&D partnerships

  • Investment in clinical trials and regulatory approvals

  • Focus on precision medicine and personalized therapies

High entry barriers exist due to regulatory complexity and scientific challenges.

Key Players in the Microbiome Therapeutics Market

Major companies operating in the global market include:

  • Seres Therapeutics (U.S.)

  • Finch Therapeutics Group, Inc. (U.S.)

  • Ferring (Switzerland)

  • MaaT Pharma (France)

  • Vedanta Biosciences, Inc. (U.S.)

  • Nestlé Health Science (Switzerland)

  • Evelo Biosciences (U.S.)

  • Enterome (France)

  • Synlogic (U.S.)

Key Industry Development:

  • May 2025: Ferring showcased initial findings from the investigational Phase 3b multi-center, single-arm CDI-SCOPE study evaluating the safety and effectiveness of REBYOTA (fecal microbiota, live – jslm) when administered by colonoscopy.

  • June 2024: Nestlé Health Science acquired global rights to Vowst from Seres Therapeutics, Inc. The transaction allowed the company to have complete control over the further development, commercialization, and manufacturing of VOWST in the US and worldwide.

About Us:

Fortune Business Insights™ delivers accurate data and innovative corporate analysis, helping organizations of all sizes make appropriate decisions. We tailor novel solutions for our clients, assisting them to address various challenges distinct to their businesses. Our aim is to empower them with holistic market intelligence, providing a granular overview of the market they are operating in.

Contact Us:

Fortune Business Insights Pvt. Ltd.

9th Floor, Icon Tower,

Baner - Mahalunge Road, Baner,

Pune-411045, Maharashtra, India.

Phone:

US: +18339092966

UK: +448085020280

APAC: +91 744 740 1245Email: sales@fortunebusinessinsights.com


 
 
 

Comments

bottom of page